FDA Approves Opdivo to treat advanced form of kidney cancer

The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced renal cell carcinoma. As per IQ4I analysis, Mab commanded the largest revenue of $XX million of the immunotherapeutics global market in 2014. For more info http://iq4i.com/www/home/news or email us at bd@iq4i.com

 

Advertisements

One thought on “FDA Approves Opdivo to treat advanced form of kidney cancer

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s